But this comes in second-line breast cancer, a use the group isn’t pursuing.

Varseta-M efficacy wanes, but more than justifies a pivotal trial.

Ascentage hopes to become a new force in BTK.

Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.

Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.

Tacti-004 is terminated for futility, and Immutep crashes 89%.